Incyte | INCY - Trade Debtors



Incyte reported $842.89M in Trade Debtors for its fiscal quarter ending in June of 2025.


Trade Debtors Change Date
Acadia Pharmaceuticals USD 119.69M 5.97M Jun/2025
Agios Pharmaceuticals USD 4.99M 1.64M Jun/2025
Alnylam Pharmaceuticals USD 567.11M 149.08M Jun/2025
Amgen USD 8.7B 569M Jun/2025
Biogen USD 2.08B 87.5M Jun/2025
BioMarin Pharmaceutical USD 855.85M 116.68M Jun/2025
Bristol-Myers Squibb USD 15.1B 515M Jun/2025
Eli Lilly USD 17.21B 3.2B Jun/2025
Exelixis USD 292.35M 10.72M Jul/2025
Gilead Sciences USD 4.78B 393M Jun/2025
Incyte USD 842.89M 19.76M Jun/2025
Ionis Pharmaceuticals USD 52.58M 12.87M Jun/2025
MacroGenics USD 12.53M 8.22M Jun/2025
Merck USD 12.72B 1.14B Jun/2025
Moderna USD 457M 151M Jun/2025
Neurocrine Biosciences USD 595.7M 79.7M Jun/2025
Novartis USD 9.18B 451M Jun/2025
Novartis USD 9.18B 1.62B Jun/2025
Pfizer USD 16.09B 1.35B Jun/2025
PTC Therapeutics USD 196.13M 14.36M Jun/2025
Regeneron Pharmaceuticals USD 5.61B 49M Jun/2025
Sarepta Therapeutics USD 609.6M 114.93M Jun/2025
Ultragenyx Pharmaceutical USD 124.46M 25.62M Jun/2025
Vertex Pharmaceuticals USD 1.89B 88.4M Jun/2025